Samarium lexidronam (¹⁵³Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma

References

• Janjan N. Bone metastases: approaches to management. Semin. Oncol.28, 28–34 (2001).
   PubMed Web of Science ®Google Scholar
• Janjan N. Palliation and supportive care in radiation medicine. Hematol. Oncol. Clin. North Am.20, 187–211 (2006).
   Google Scholar
• Samant R, Gooi AC. Radiotherapy basics for family physicians. Potent tool for symptom relief. Can. Fam. Physician51, 1496–1501 (2005).
   Google Scholar
• Reisfield GM, Silberstein EB, Wilson GR. Radiopharmaceuticals for the palliation of painful bone metastases. Am. J. Hosp. Palliat. Care22, 41–46 (2005).
   PubMedGoogle Scholar
• Anderson P. Samarium for osteoblastic bone metastases and osteosarcoma. Expert Opin. Pharmacother.7, 1475–1486 (2006).
   PubMed Web of Science ®Google Scholar
• Agarawal JP, Swangsilpa T, van der Linden Y et al. The role of external beam radiotherapy in the management of bone metastases. Clin. Oncol. (R. Coll. Radiol.)18, 747–760 (2006).
   PubMed Web of Science ®Google Scholar
• Hillegonds DJ, Franklin S, Shelton DK et al. The management of painful bone metastases with an emphasis on radionuclide therapy. J. Natl Med. Assoc.99, 785–794 (2007).
   Google Scholar
• Lam MG, de Klerk JM, van Rijk PP, Zonnenberg BA. Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases. Anticancer Agents Med. Chem.7, 381–397 (2007).
   PubMed Web of Science ®Google Scholar
• Lin A, Ray ME. Targeted and systemic radiotherapy in the treatment of bone metastasis. Cancer Metastasis Rev.25, 669–675 (2006).
   PubMed Web of Science ®Google Scholar
• Toegel S, Hoffmann O, Wadsak W et al. Uptake of bone-seekers is solely associated with mineralisation! A study with 99mTc-MDP, 153Sm-EDTMP and 18F-fluoride on osteoblasts. Eur. J. Nucl. Med. Mol. Imaging33, 491–494 (2006).
   PubMed Web of Science ®Google Scholar
• Goeckeler WF, Troutner DE, Volkert WA et al. 153Sm radiotherapeutic bone agents. Int. J. Rad. Appl. Instrum. [B]13, 479–482 (1986).
   PubMedGoogle Scholar
• Atkins HL, Srivastava SC. Radiolabeled bone-seeking radiopharmaceuticals. Q. J. Nucl. Med.40, 285–289 (1996).
   Google Scholar
• Goeckeler WF, Edwards B, Volkert WA et al. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J. Nucl. Med.28, 495–504 (1987).
   PubMed Web of Science ®Google Scholar
• Ramamoorthy N, Saraswathy P, Das MK et al. Production logistics and radionuclidic purity aspects of 153Sm for radionuclide therapy. Nucl. Med. Commun.23, 83–89 (2002).
   Google Scholar
• Vimalnath KV, Das MK, Ananthakrishnan M, Ramamoorthy N. Facile access to 154Eu, a new reference source for calibration in γ-ray spectrometry. Appl. Radiat. Isot.62, 17–23 (2005).
   Google Scholar
• Coursey BM, Hoppes DD, Schima FJ, Unterweger MP. The standardization of samarium-153. Int. J. Rad. Appl. Instrum. [A]38, 31–34 (1987).
   Google Scholar
• Quadramet®. In: Physician’s Desk Reference Product Information (61st Edition). Thompson PDR, NJ, USA 1040–1042 (2007).
   Google Scholar
• van Rensburg AJ, Alberts AS, Louw WK. Quantifying the radiation dosage to individual skeletal lesions treated with samarium-153-EDTMP. J. Nucl. Med.39, 2110–2115 (1998).
   Google Scholar
• Goeckeler WF, Stoneburner LK, Kasi LP et al. Analysis of urine samples from metastatic bone cancer patients administered 153Sm-EDTMP. Nucl. Med. Biol.20, 657–661 (1993).
   Google Scholar
• Anderson PM, Wiseman GA, Dispenzieri A et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J. Clin. Oncol.20, 189–196 (2002).
   PubMed Web of Science ®Google Scholar
• Louw WK, Dormehl IC, van Rensburg AJ et al. Evaluation of samarium-153 and holmium-166-EDTMP in the normal baboon model. Nucl. Med. Biol.23, 935–940 (1996).
   Google Scholar
• Bayouth JE, Macey DJ. Dosimetry considerations of bone-seeking radionuclides for marrow ablation. Med. Phys.20, 1089–1096 (1993).
   Google Scholar
• Lamb HM, Faulds D. Samarium 153Sm lexidronam. Drugs Aging11, 413–419 (1997).
   Google Scholar
• Anderson PM, Wiseman GA, Erlandson L et al. Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin. Cancer Res.11, 6895–6900 (2005).
   PubMed Web of Science ®Google Scholar
• Resche I, Chatal JF, Pecking A et al. A dose-controlled study of 153Sm-ethylenediaminetetramethylene-phosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur. J. Cancer33, 1583–1591 (1997).
   PubMed Web of Science ®Google Scholar
• Sartor O, Reid RH, Hoskin PJ et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology63, 940–945 (2004).
   PubMed Web of Science ®Google Scholar
• Serafini AN, Houston SJ, Resche I et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J. Clin. Oncol16, 1574–1581 (1998).
   PubMed Web of Science ®Google Scholar
• Bruland OS, Skretting A, Solheim OP, Aas M. Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach. Acta Oncol.35, 381–384 (1996).
   PubMed Web of Science ®Google Scholar
• Mahajan A, Anderson PM, Hughes D et al. Multimodality local management of recurent osteosarcoma including radiotherapy, samarium, and chemotherapy. Pediatr. Blood Cancer (2007) (In Press).
   Google Scholar
• Mahajan A, Woo S, Kornguth D et al. Multimodality treatment of osteosarcoma: radiation in a high-risk cohort. Pediatr. Blood Cancer (2008) (In Press).
   Google Scholar
• Franzius C, Schuck A, Bielack SS. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J. Clin. Oncol.20, 1953–1954 (2002).
   PubMed Web of Science ®Google Scholar
• Franzius C, Bielack S, Flege S et al. High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma. Nuklearmedizin40, 215–220 (2001).
   PubMedGoogle Scholar
• Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics119(Suppl. 2), S150–S162 (2007).
   PubMed Web of Science ®Google Scholar
• Perez EA. Metastatic bone disease in breast cancer: the patient’s perspective. Semin. Oncol.28, 60–63 (2001).
   Google Scholar
• Coleman RE. Bisphosphonates in breast cancer. Ann. Oncol.16, 687–695 (2005).
   PubMed Web of Science ®Google Scholar
• Hoskin PJ. Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat. Rev.29, 321–327 (2003).
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Theriault RL, Lipton A et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J. Clin. Oncol.16, 2038–2044 (1998).
   PubMed Web of Science ®Google Scholar
• Wu S, Dahut WL, Gulley JL. The use of bisphosphonates in cancer patients. Acta Oncol.46, 581–591 (2007).
   PubMedGoogle Scholar
• Gralow J, Tripathy D. Managing metastatic bone pain: the role of bisphosphonates. J. Pain Symptom Manage.33, 462–472 (2007).
   PubMed Web of Science ®Google Scholar
• Diel IJ. Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review. Support Care Cancer15(11), 1243–1249 (2007) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Santini D, Fratto ME, Vincenzi B et al. Zoledronic acid in the management of metastatic bone disease. Expert Opin. Biol. Ther.6, 1333–1348 (2006).
   PubMed Web of Science ®Google Scholar
• Saad F, Lipton A. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int.96, 964–969 (2005).
   PubMed Web of Science ®Google Scholar
• Marcus CS, Saeed S, Mlikotic A et al. Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP. Clin. Nucl. Med.27, 427–430 (2002).
   PubMed Web of Science ®Google Scholar
• Wang RF, Zhang CL, Zhu SL, Zhu M. A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer. Med. Princ. Pract.12, 97–101 (2003).
   Google Scholar
• Yeh HS, Swift RA, Ferretti D et al. Phase I study of bortezomib and 153Sm-lexodronam combination for refractory and relapsed myeloma. J. Clin. Oncol.24, S450 (2006).
   Google Scholar
• Mahajan A, Anderson PM, Hughes D et al. Multimodality local management of recurrent osteosarcoma including radiotherapy, samarium, and chemotherapy. Pediatr. Blood Cancer47, 501 (2006).
   Google Scholar
• Morris M, Pandit-Taskar N, Amodio A et al. Phase I study of docetaxel and 153-Sm-lexidronam repetitively administered for castrate metastatic prostate cancer. J. Clin. Oncol.25(Suppl. 18), 272 (2007) (Abstract 5152).
   Google Scholar
• Yeh H, Swift R, Ferretti D et al. Phase I study of bortezemib and 153-Sm-lexidronam combination for refractory and relasped multiple myeloma. J. Clin. Oncol. Proc. ASCO 2007.
   Google Scholar
• Tu SM, Millikan RE, Mengistu B et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised Phase II trial. Lancet357, 336–341 (2001).
   PubMed Web of Science ®Google Scholar
• Menda Y, Bushnell DL, Williams RD et al. Efficacy and safety of repeated samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain. Clin. Nucl. Med.25, 698–700 (2000).
   PubMed Web of Science ®Google Scholar
• Turner JH, Claringbold PG. A Phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetra-methylene phosphonate. Eur. J. Cancer27, 1084–1086 (1991).
   PubMed Web of Science ®Google Scholar
• Sartor O, Reid RH, Bushnell DL et al. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer109, 637–643 (2007).
   PubMed Web of Science ®Google Scholar
• Anderson P, Aguilera D, Pearson M, Woo S. Outpatient chemotherapy + radiotherapy in sarcomas: improving cancer control with radiosensitizing agents. Review of ifosfamide, glufosfamide, gemcitabine, sapacitabine, samarium, methotrexate, temozolomide, and irinotecan regimens during radiation. Cancer Control (2007) (In Press).
   Google Scholar
• Loblaw DA, Wu JS, Kirkbride P et al. Pain flare in patients with bone metastases after palliative radiotherapy – a nested randomized control trial. Support Care Cancer15, 451–455 (2007).
   PubMedGoogle Scholar
• Dafermou A, Colamussi P, Giganti M et al. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur. J. Nucl. Med.28, 788–798 (2001).
   PubMedGoogle Scholar
• Farhanghi M, Holmes RA, Volkert WA et al. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J. Nucl. Med.33, 1451–1458 (1992).
   PubMedGoogle Scholar
• Trotti A, Colevas AD, Setser A et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin. Radiat. Oncol.13, 176–181 (2003).
   PubMed Web of Science ®Google Scholar
• Turner JH, Claringbold PG, Hetherington EL et al. A Phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. J. Clin. Oncol.7, 1926–1931 (1989).
   PubMed Web of Science ®Google Scholar
• Applebaum FR, Sandmaier B, Brown PA. Myelosuppression and mechanism of recovery following administration of 153Samarium-EDTMP. Antibody Immunoconj.1, 263–279 (1988).
   Google Scholar
• Turner JH, Claringbold PG, Berger JD et al. 153Sm-EDTMP and melphalan chemoradiotherapy regimen for bone marrow ablation prior to marrow transplantation: an experimental model in the rat. Nucl. Med. Commun.13, 321–329 (1992).
   PubMed Web of Science ®Google Scholar
• Bartlett ML, Webb M, Durrant S et al. Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies. Eur. J. Nucl. Med. Mol. Imaging29, 1470–1477 (2002).
   PubMed Web of Science ®Google Scholar
• Macfarlane DJ, Durrant S, Bartlett ML et al. 153Sm EDTMP for bone marrow ablation prior to stem cell transplantation for haematological malignancies. Nucl. Med. Commun.23, 1099–1106 (2002).
   PubMed Web of Science ®Google Scholar
• Hogan WJ, Lacy MQ, Wiseman GA et al. Successful treatment of POEMS syndrome with autologous hematopoietic progenitor cell transplantation. Bone Marrow Transplant.28, 305–309 (2001).
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Wiseman GA, Lacy MQ et al. A Phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia19, 118–125 (2005).
   PubMed Web of Science ®Google Scholar
• Kennedy GA, Durrant S, Butler J et al. Outcome of myeloablative allogeneic stem cell transplantation in multiple myeloma with a 153Sm-EDTMP-based preparative regimen. Leukemia19, 879–880 (2005).
   Google Scholar
• Rodriguez V, Erlandson L, Arndt CA et al. Low toxicity and efficacy of (153)samarium-EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemia. Pediatr. Transplant.9, 122–126 (2005).
   PubMed Web of Science ®Google Scholar
• Rodriguez V, Anderson PM, Litzow MR et al. Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia. Leuk. Lymphoma47, 1583–1592 (2006).
   PubMed Web of Science ®Google Scholar
• Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol.6, 392–400 (2005).
   PubMed Web of Science ®Google Scholar
• Etchebehere EC, Pereira Neto CA, Lima MC et al. Treatment of bone pain secondary to metastases using samarium-153-EDTMP. Sao Paulo Med. J.122, 208–212 (2004).
   Google Scholar
• Sapienza MT, Ono CR, Guimaraes MI et al. Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy. Rev. Hosp. Clin. Fac. Med. Sao Paulo59, 321–328 (2004).
   Google Scholar
• Tap WD, Federman N, Eilber FC. Targeted therapies for soft-tissue sarcomas. Expert Rev. Anticancer Ther.7, 725–733 (2007).
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov.5, 769–784 (2006).
   PubMed Web of Science ®Google Scholar
• Issa JP. DNA methylation as a therapeutic target in cancer. Clin. Cancer Res.13, 1634–1637 (2007).
   PubMed Web of Science ®Google Scholar
• Wurdinger T, Costa FF. Molecular therapy in the microRNA era. Pharmacogenomics J.7, 297–304 (2007).
   PubMed Web of Science ®Google Scholar
• Watanabe M, Takagi A, Matsuzaki T et al. Knowledge of epigenetic influence for prostate cancer therapy. Curr. Cancer Drug Targets6, 533–551 (2006).
   Google Scholar
• DeLaney TF, Trofimov AV, Engelsman M, Suit HD. Advanced-technology radiation therapy in the management of bone and soft tissue sarcomas. Cancer Control12, 27–35 (2005).
   PubMedGoogle Scholar
• Lee CT, Bilton SD, Famiglietti RM et al. Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques? Int. J. Radiat. Oncol. Biol. Phys.63, 362–372 (2005).
   PubMed Web of Science ®Google Scholar
• Anderson P, Salazar-Abshire M. Improving outcomes in difficult bone cancers using multimodality therapy, including radiation: physician and nursing perspectives. Curr. Oncol. Rep.8, 415–422 (2006).
   PubMedGoogle Scholar
• Callstrom MR, Atwell TD, Charboneau JW et al. Painful metastases involving bone: percutaneous image-guided cryoablation-prospective trial interim analysis. Radiology241, 572–580 (2006).
   PubMed Web of Science ®Google Scholar
• Callstrom MR, Charboneau JW, Goetz MP et al. Image-guided ablation of painful metastatic bone tumors: a new and effective approach to a difficult problem. Skeletal Radiol.35, 1–15 (2006).
   PubMed Web of Science ®Google Scholar
• Anderson PM. Effectiveness of radiotherapy for osteosarcoma that responds to chemotherapy. Mayo. Clin. Proc.78, 145–146 (2003).
   PubMedGoogle Scholar
• Machak GN, Tkachev SI, Solovyev YN et al. Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. Mayo Clin. Proc.78, 147–155 (2003).
   PubMed Web of Science ®Google Scholar
• Tong RT, Boucher Y, Kozin SV et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res.64, 3731–3736 (2004).
   PubMed Web of Science ®Google Scholar
• Gorski DH, Beckett MA, Jaskowiak NT et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res.59, 3374–3378 (1999).
   PubMed Web of Science ®Google Scholar
• Liepe K, Runge R, Kotzerke J. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. J. Cancer Res. Clin. Oncol.131, 60–66 (2005).
   Google Scholar
• Lewington VJ. Cancer therapy using bone-seeking isotopes. Phys. Med. Biol.41, 2027–2042 (1996).
   Google Scholar
• Lewington VJ. Bone-seeking radionuclides for therapy. J. Nucl. Med.46(Suppl. 1), S38–S47 (2005).
   PubMed Web of Science ®Google Scholar
• Liepe K, Hliscs R, Kropp J et al. Rhenium-188-HEDP in the palliative treatment of bone metastases. Cancer Biother. Radiopharm.15, 261–265 (2000).
   Google Scholar
• Liepe K, Hliscs R, Kropp J et al. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. J. Nucl. Med.44, 953–960 (2003).
   Google Scholar
• Liepe K, Runge R, Kotzerke J. Systemic radionuclide therapy in pain palliation. Am. J. Hosp. Palliat. Care22, 457–464 (2005).
   Google Scholar
• Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the α-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin. Cancer Res.12, S6250–S6257 (2006).
   PubMed Web of Science ®Google Scholar
• Nilsson S, Larsen RH, Fossa SD et al. First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases. Clin. Cancer Res.11, 4451–4459 (2005).
   PubMed Web of Science ®Google Scholar
• Henriksen G, Fisher DR, Roeske JC et al. Targeting of osseous sites with α-emitting 223Ra: comparison with the β-emitter 89Sr in mice. J. Nucl. Med.44, 252–259 (2003).
   PubMed Web of Science ®Google Scholar